BioTuesdays

Author - Melane Sampson

Precision Biosciences

FDA clears Precision’s IND for PBGENE-DMD

Precision BioSciences (NASDAQ: DTIL) has announced that the FDA has granted a Study May Proceed notification, allowing initiation of clinical trial site activation for the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD in...

BioSyent

BioSyent to acquire Oral Science

BioSyent (TSXV: RX) has entered into a Share Purchase Agreement to acquire closely held Oral Science, a Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard...

Ocugen Logo

Rita Johnson-Greene joins Ocugen as CFO

Ocugen (NASDAQ: OCGN) has appointed Rita Johnson-Greene as chief financial officer (CFO). Ms. Johnson-Greene brings more than 20 years of healthcare experience to the role. Most recently, she served as chief operating...

Cognition Logo

Cognition lengthens Zervimesine program in DLB

Cognition Therapeutics (NASDAQ: CGTX) has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB) from the original 12 months to include several more months of treatment. According...

Marvel Biosciences Logo

JPO grants patent to Marvel for MB-204

Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) has been granted a patent for its lead therapeutic candidate MB-204 by the Japanese Patent Office (JPO) covering composition of matter and methods of use claims. MB-204 is a...